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1366why the studies have failed (10).
In these trials, it appears thatSee page 1373patient selection may have played
a larger role in the disappointing
results than treatment alone.
We have previously shown that
N-terminal pro–B-type natri-
uretic peptide (NT-proBNP) hasan excellent predictive value for both short- and intermediate-
term cardiovascular events in patients with diabetes (11–13).
Similarly, the authors of the STENO-2 (multifactorial
intervention and cardiovascular disease in patients with type 2
diabetes) study, which is one of the rare studies that accom-
plished a substantial cardiovascular risk reduction, recognized
that the pre-selection variable “microalbuminuria” was asso-
ciated with a signiﬁcant risk only if an increased NT-proBNP
concentration was also found in patients (14).
The rationale of the prospective trial described in this
report was based on 2 assumptions. First, that NT-proBNP
was the best marker to identify diabetic patients at risk for
cardiac disease in our prior studies. This biomarker can be
considered an integral of the most important cardiac risk
markers in diabetes mellitus, as this marker not only mirrors
the presence but also the severity of the burden on the
cardiovascular system. Second, renin-angiotensin system
(RAS) antagonists and beta-blockers are two key therapies
in cardiology and are well established for primary and
secondary prevention of cardiac events.
We hypothesized accordingly that the up-titration of
RAS antagonists such as ACE inhibitors or angiotensinogen
II receptor blockers and beta-blockers would be most
effective for the prevention of cardiac events in a pre-deﬁned
subgroup of diabetes mellitus patients with increased NT-
proBNP concentrations at baseline.
Methods
Study design. Patients with diabetes mellitus type 2 were
enrolled in the study between November 20, 2007, and
January 12, 2010. The observation period continued until
the last patient exited the study on January 12, 2012.
Inclusion criteria were known type 2 diabetes for at least 6
months, age 18 years of age, NT-proBNP concentrations
>125 pg/ml, and willingness to participate. The target value
of 125 pg/ml was chosen as our prior data had shown that
this is an excellent threshold for risk prediction in this
population (11). Cardiac disease–based exclusion criteria
were one or more of the following: history of cardiac disease;
signs of cardiac disease in the electrocardiogram such as
atrial ﬁbrillation; ST-T-wave abnormalities or a bundle
branch block; abnormal echocardiography (with the excep-
tion of diastolic dysfunction), deﬁned as low ejection
fraction; wall motion abnormalities, signiﬁcant valvedysfunction, or other signiﬁcant alteration. Other exclusion
criteria were a disease other than diabetes lowering the
patient’s life expectancy to <1 year, chronic infections or
malignancies, systemic treatment with cortisone, renal
replacement therapy, and for women of childbearing age the
absence of reliable contraception. For the patient ﬂow
diagram, see Figure 1.
An experienced study nurse screened consecutive
patients from 4 specialized diabetes centers (see subsequent
sections) for participation in the study. If eligible, patients
were invited to the tertiary cardiac care unit for detailed
information about the study protocol. Informed consent
was obtained from participating patients. Three hundred
patients were prospectively digitally randomized 1:1 into
a control group that was cared for at 4 different specialized
diabetes care units and an intensiﬁed group that was
additionally treated at the cardiac outpatient clinic of the
Medical University of Vienna. The diabetes care units
were the diabetic care outpatient departments of the
Medical University of Vienna and of Hietzing Hospital, as
well as 2 centers run by the Vienna Health Insurance Fund
(Wiener Gebietskrankenkasse). All 4 centers employ
experienced staff, and therapy was given based on current
guidelines. (15)
A detailed medical history was taken for each patient at
the baseline visit in the cardiac outpatient clinic to obtain
information about concomitant diseases and current treat-
ment. A 12-lead electrocardiogram was recorded, and an
echocardiogram was performed. Blood pressure was
measured in the supine position after 20-min rest, and
blood was drawn from every patient. NT-proBNP was
determined by a commercially available point-of-care
system (COBAS H232, Roche Diagnostics Rotkreuz,
Switzerland). To measure additional risk markers for
cardiovascular disease, cholesterol (especially low-density
lipoprotein cholesterol) from fasting samples was
measured and HbA1c was determined. Kidney function was
determined by measuring serum-creatinine; the estimated
glomerular ﬁltration rate (eGFR) was calculated using the
MDRD (Modiﬁcation of Diet in Renal Disease) formula.
Albuminuria was determined as the albumin/creatinine
ratio from spot urine.
All patients visited the clinics at baseline and after 3, 6,
and 12 months. At that time the functional status of patients
was assessed, current treatment was recorded, and lab-based
parameters were measured. Data were collected by the dia-
betes unit (control group) and the cardiac care unit (inten-
siﬁed group) of the Medical University of Vienna at every
scheduled visit and computerized by a cardiologist who was
not involved in the patients’ care. For all patients, guideline-
based treatments were initiated if not yet established (15).
Speciﬁcally, all patients received antiplatelet therapy and
lipid lowering agents if appropriate, and antihyperglycemic
therapy was optimized by a diabetologist.
Patients in the intensiﬁed group had additional individ-
ualized visits for the initiation and up-titration of RAS
Figure 1 Flow Diagram
Enrollment, randomization, and follow-up of study participants.
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1367antagonists and beta-blockers. In the intensiﬁed group,
patients received a treatment logbook at their initial visit. In
this logbook the physician noted the individual weekly
titration steps, normally for the upcoming month. This way
the dosage was increased very slowly (normally on a weekly
basis) but steadily. Patients were instructed to measure blood
pressure and heart rate at home and to record values. In case
of hypotension (systolic blood pressure <100 mm Hg),
bradycardia (heart rate <55 beats/min), or the onset of any
new symptom before reaching the maximum dosage, they
were advised to phone the outpatient unit. The physician
then decided if the medication could be further up-titrated
safely.
If the patient was already prescribed a RAS antagonist and
a beta-blocker, these agents were titrated to the maximum
recommended dosages. If the patient was not already
prescribed a RAS antagonist, an ACE inhibitor was initiated.
The same was true for beta-blockers. If the patient was not on
any neurohumoral medication, the patient received an ACE
inhibitor ﬁrst; beta-blockers were prescribed in a second step.
Physicians increased the dosage of the medications until
either NT-proBNP concentrations decreased by 50% or
below normal values or a maximum recommended or toler-
ated dose was reached (see subsequent sections). Up-titration
of therapy was scheduled within the ﬁrst 3 months. Thecardiologist was not involved in lifestyle recommendations
or hospitalizations. Patients went for scheduled visits over
a period of 1 year in the intensiﬁed group. The observation
period for all patients was 2 years.
The study was conducted in accordance with the Helsinki
II declaration and was approved by the ethics committee of
the Medical University of Vienna. All participants
gave written informed consent. The study was registered
with clinical trial number NCT00562952.
Endpoints. The endpoints were assessed 2 years after the
baseline visit of each patient. The primary endpoint was
hospitalization or death due to cardiac disease.
Secondary endpoints were all-cause hospitalization, un-
planned cardiovascular hospitalizations or death, and heart
failure hospitalizations. A cardiovascular event was deﬁned as
any unplanned hospitalization or any death based on a cardiac
or other macrovascular event. An additional secondary
endpoint was a decrease of NT-proBNP concentrations after
1 year of intensiﬁed treatment.
Mortality data were obtained from the Austrian Central
Ofﬁce of Civil Registration (Zentrales Melderegister).
Hospitalization information was obtained from the regional
hospital data network (Krankenanstaltenverbund). The pri-
mary reasons for hospitalization were deduced from hospital
ﬁles by a cardiologist who was not aware of the results at
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1368the time of indexing or the randomization. The physician
responsible was contacted for cases that were unclear.
Statistical analysis. The required sample size was calcu-
lated based on an expected event rate of 2% versus 9%,
respectively, for the Fisher exact test, an alpha level at 0.05
and 1-beta ¼ 0.80. Post hoc results revealed an actual power
of 0.63 for the primary endpoint. Metric variables were
presented as mean  SD. Frequencies of categorical data
were given by absolute numbers and percentages. Differ-
ences between groups were tested with the Student t test for
metric variables, Fisher exact test for dichotomous variables,
and the chi-square test for categorical data with more than 2
categories. Differences between baseline and follow-up were
tested with respect to the data level either with paired-
samples t test, the McNemar test, the Cochran’s Q test, or
the Wilcoxon matched-pairs signed rank test (for NT-
proBNP after log-transformation).
Due to the nonlinear and nonnormal value distribution of
NT-proBNP, this parameter was presented as the median
and interquartile range. Differences in the value distribution
between groups were tested with the nonparametric 2-
sample Kolmogorov-Smirnov test.
We used the Kaplan-Meier method to estimate cumula-
tive event-free survival functions and used a stratiﬁed log-
rank test to compare the control and the intensiﬁed group.
An additional Kaplan-Meier model was calculated including
patients who did not participate in the study based on low
(<125 pg/ml) NT-proBNP concentrations but who had
given informed consent for further analysis.
We used unadjusted Cox regression models in order to
test differences between the control and the intensiﬁed
group. Additionally, we also calculated Cox models adjusted
for age and log-transformed NT-proBNP concentrations
at baseline for all endpoints. All results from the regression
models were presented using hazard ratios EXP(B). Hazard
ratios are given per unit increment. A p value of 0.05 was
considered to indicate statistical signiﬁcance for all tests.
All analyses were performed with SPSS software (version
18.0.0, Chicago, Illinois).Table 1 Baseline Characteristics
Con
Age, yrs
Duration of diabetes, yrs
Female
History of hypertension
History of nicotine use
History of alcohol use
Chronic obstructive lung disease
Body mass index, kg/m2
Retinopathy (stage 0/1/2/3)
Peripheral artery occlusive disease
Peripheral artery occlusive disease (stage 0/1/2/3/4)
Cerebral vascular disease
Peripheral neuropathy
Values are mean SD or %.Results
Patients’ characteristics at baseline and after 1 year. Com-
plete demographic data of the patients and differences
between the parameters measured are described in Tables 1
and 2. For medication at baseline and target doses of medi-
cation for the entire cohort, see Online Table 1.
In the control group, 131 patients completed the study
according to the study protocol, and 137 patients in the
intensiﬁed group completed the study according to the
protocol (Fig. 1).
After 12 months there was a signiﬁcant difference
between the control and intensiﬁed groups in both the
number of patients treated with RAS antagonists and beta-
blockers and in the dosage reached (p < 0.0001 for all). RAS
antagonists were up-titrated to 100% of the recommended
dosage in 79% of cases in the intensiﬁed group compared
with 42% in the control group (p < 0.0001). Beta-blockers
were up-titrated to 100% of the recommended dosage in
51% of cases in the intensiﬁed group and in only 10% of
cases in the control group (p < 0.0001). A combination of
100% of the RAS antagonist and 100% of the beta-blocker
recommended dosage was achieved in 46% of cases in the
intensiﬁed group and in 5% of cases in the control group
(p < 0.0001). Patients in the intensiﬁed group went to an
average of 1.36  0.96 additional visits. Reasons for not up-
titrating to 100% of the recommended dosage were hypo-
tension, bradycardia (<55 beats/min), nonadherence of the
patient, or down-titration of medication by the primary care
physician. Four patients in the intensiﬁed group were not
up-titrated to the maximum dosage due to the development
of normal NT-proBNP concentrations.
Blood pressure was signiﬁcantly and similarly reduced in
both groups after 12 months (p ¼ 0.003 control group,
p ¼ 0.002 intensiﬁed group). Heart rate was reduced only in
the intensiﬁed group (p ¼ 0.004).
Changes in NT-proBNP. There was no signiﬁcant
decrease in NT-proBNP concentrations after 1 year in
the intensiﬁed group. The control group NT-proBNPtrol (n ¼ 150) Intensiﬁed (n ¼ 150) p Value
67.2  9.6 67.8  8.5 NS
16  12 15  13 NS
43.3 41.3 NS
89 93 NS
44 40 NS
9 6 NS
5 5 NS
31  7 30  6 NS
84/6/8/2 87/7/4/1 NS
15 13 NS
85/7/3/2/2 87/7/2/1/3 NS
15 7 NS
31 17 0.007
Table 2 Baseline Characteristics and Follow-Up Values
Control Baseline
(n ¼ 150)
Intensiﬁed Baseline
(n ¼ 150) p Value
Control 12 Months
(n ¼ 131)
Intensiﬁed 12 Months
(n ¼ 137) p Value
Blood pressure systolic, mm Hg 151  22 151  23 0.10 144  22* 145  22* 0.83
Heart rate, beats/min 72  11 72  12 0.78 72  12 68  11* 0.004
RAS antagonist, % 79 77 0.78 78 95* 0.0001
RAS % target dose 55  40 57  42 0.59 74  31* 92  30* 0.0001
Beta-blocker, % 45 54 0.13 44 85* 0.0001
Beta-blocker % target dose 24  32 32  35 0.05 54  29* 80  31* 0.0001
Statins 71 (47.3%) 72 (48.0%) 0.10 61 (40.7%) 70 (46.7%) 0.17
Aspirin 62 (41.3%) 63 (42.0%) 1.0 51 (34.0%) 63 (42.0%) 0.098
Oral antidiabetic drugs 68 (45.3%) 71 (47.3%) 0.62 61 (40.7%) 67 (44.7%) 0.62
Insulin 45 (30.0%) 42 (28.0%) 0.73 44 (29.3%) 35 (23.3%) 0.12
Triglycerides, mg/dl 154  76 152  70 0.83 146  85 151  85 0.63
LDL cholesterol, mg/dl 96  33 94  29 0.34 94  32 89  29* 0.21
eGFR, ml/min 81.5  18.2 82.9  18.2 0.51 82.2  18.7 77  17.6* 0.14
HbA1c, % 6.9  1 7.1  1.1 0.27 7.1  1.2* 7.1  1 0.78
NT-proBNP, pg/ml 266 (181–402) 235 (169–343) 0.18 264 (167–394) 248 (169–433) 0.65
Values are mean  SD, %, n (%), or median (interquartile range). *p < 0.05 baseline versus 12 months within a group. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. To
convert the values for triglycerides to millimoles per liter, multiply by 0.01129. To convert the values for creatinine to micromoles per liter, multiply by 88.4.
eGFR ¼ estimated glomerular ﬁltration rate; NT-proBNP: N-terminal pro–B-type natriuretic peptide; RAS ¼ renin-angiotensin system.
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1369concentrations were comparable to concentrations in the
intensiﬁed group after 1 year (Table 2). Among the patients
that followed the scheduled visits (per protocol patients),
13 patients in each group developed normal concentrations
of NT-proBNP (125 pg/ml). Of the 13 patients in the
intensiﬁed group, 9 patients were treated with 100% of the
RAS antagonist and beta-blocker dosage.
Safety. Potential side effects that would require hospitali-
zation, such as hypotension, bradycardia, dizziness, hyper-
kalemia, or worsening kidney function, were not observed.
One patient who experienced a cough under ACE inhibitor
treatment was changed to an angiotensin II receptor blocker.
Of note, there was a signiﬁcant decrease of the estimated
glomerular ﬁltration rate overall in the intensiﬁed group
(Table 2).
Outcome. Three patients in the intensiﬁed group and 5
patients in the control group died during the observation
period. In the intensiﬁed group all witnessed deaths were
noncardiac. One patient in this group died unwitnessed at
home; this case was calculated as a cardiac death. In the control
group, 3 of the 5 deaths were due to cardiac disease. Each
patient who died due to a cardiac event had a cardiac hospi-
talization prior to death. For hospitalization data, see Table 3.
Kaplan-Meier analysis. The Kaplan-Meier analysis showed
differences between the 2 groups for the primary endpoint.
The difference was statistically signiﬁcant (p ¼ 0.035)
(Fig. 2). The same was true for the endpoints: all causeTable 3 Reasons for Hospitalizations
Hospitalization Due to All Control Intensiﬁed p Value
Any reason 135 (45%) 77 (51%) 58 (39%) 0.02
Cardiovascular event 25 (8%) 18 (12%) 7 (5%) 0.02
Cardiac event 19 (6%) 14 (9%) 5 (3%) 0.03
Heart failure 8 (3%) 7 (5%) 1 (1%) 0.003
Values are n (%).hospitalization (p ¼ 0.015), unplanned cardiovascular hospi-
talization/death due to cardiovascular disease (p ¼ 0.046),
and heart failure hospitalization (p ¼ 0.031).
In the Kaplan-Meier model where we added the group of
patients who did not enter the study solely based on low NT-
proBNP (<125 pg/ml) there was a signiﬁcant difference in
the primary endpoint between the control group and the group
with lowNT-proBNPconcentrations.Therewas nodifference
in survival between the intensiﬁed group and patients with low
NT-proBNP concentrations (Online Fig. 1).
Cox regression models. Regarding the primary endpoint
hospitalization or death due to cardiac disease, there wasFigure 2
Kaplan-Meier Curves of the Primary Endpoint
Hospitalization or Death Due to Cardiac Disease
According to Treatment Strategy
Red line ¼ intensiﬁed group. Blue line ¼ control group. Log-rank test for overall
difference, p ¼ 0.035.
Table 4 Cox Regression Models (Unadjusted)
Endpoints Hazard Ratio
95% Conﬁdence
Interval p Value
Primary endpoint 0.351 0.127–0.975 0.04
All-cause hospitalizations 0.657 0.465–0.927 0.02
Unplanned cardiovascular
hospitalizations or death
0.376 0.157–0.899 0.03
Heart failure hospitalizations 0.140 0.017–1.137 0.07
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1370a signiﬁcant difference between groups (hazard ratio: 0.351;
95% conﬁdence interval: 0.127 to 0.975; p ¼ 0.044).
A similar signiﬁcant difference was seen for the secondary
endpoints; see Table 4.
For all models adjusted for age and baseline log-
transformed or absolute NT-proBNP, see Online Tables 2
and 3.
Changes in blood pressure between baseline and follow-
up were not signiﬁcant for any endpoint evaluated. Also,
changes in heart rate did not inﬂuence outcome. Changes
were calculated as absolute values and percentage of change.Discussion
The PONTIAC (NT-proBNP Selected PreventiOn of
cardiac eveNts in a populaTion of dIabetic patients without
A history of Cardiac disease) study tested a primary preven-
tive effect of combined neurohumoral therapy against hos-
pitalization or death due to cardiac disease in patients with
type 2 diabetes mellitus. Patient pre-selection using NT-
proBNP concentration appears to identify diabetes patients
who will beneﬁt from neurohumoral therapy. The lack of
any side effects requiring hospitalization during the study
allows us to conclude that targeted blocking of neurohumoral
activation in these patients is effective and safe. Remarkably,
the preventive effect was already apparent after 2 years of
observation, although the patients had an excellent back-
ground therapy concerning blood glucose and lipid goals.
Diabetes mellitus is a heterogeneous disease. It is well
known from clinical practice that the cardiovascular risk of
individual diabetes patients varies widely. Therefore, it seems
possible that only certain subpopulations are at risk for the
development of cardiac diseases (16). As outlined in the
introduction, most studies with diabetes patients have failed
to ﬁnd a beneﬁcial effect of standard therapy on cardiovascular
outcome (1,2,7,8). Apart from the statistical weakness of low
event rates in these studies, it can be argued that the reason for
the disappointing study results might be not the drugs
investigated but the wrong patient selection. This might also
account for the contradictory results seen in the ONTAR-
GET (ONgoing Telmirsatan Alone and in Combination
with Ramipril Global Endpoint Trial) and ROADMAP
(Randomized Olmesartan And Diabetes Microalbuminuria
Prevention) studies, where the same class of drugs both
decreased and increased cardiovascular events (8,17).
Previous studies demonstrated that NT-proBNP is an
excellent predictor of long-term cardiac risk in patientswith diabetes mellitus (14,18–20). Recently, we compared
NT-proBNP with other important cardiac risk markers in
diabetes and found that NT-proBNP has a greater predic-
tive value in both the short and intermediate term (11,12).
These factors strongly argue for the utility of NT-proBNP
as the primary risk indicator for cardiac events.
The HOPE (Heart Outcomes Prevention Evaluation) and
the STENO-2 trials were both successful studies using ACE
inhibitors for the secondary prevention of cardiac events
(6,21). As the majority of patients in both trials had a history
of cardiovascular disease, the beneﬁcial effect of both ACE
inhibitor and angiotensin receptor blocker therapy is not
surprising (22). What is more important in the context of the
current study is that the authors tested post hoc the inﬂuence
of NT-proBNP concentrations and found that it was
primarily the patients with NT-proBNP concentrations
above the median value who impacted the event rate (14).
The inﬂuence of beta-blockers on the primary or
secondary prevention of cardiac disease in patients with
diabetes mellitus is completely unknown, but from a patho-
physiological perspective, counteracting the known over-
stimulated sympathetic nervous system is an interesting
concept (23). As a means for secondary prevention in
patients with cardiac disease, these agents have been estab-
lished as an effective therapy for some time.
Unlike most previous studies in the ﬁeld, we did not
deﬁne traditional treatment goals regarding blood pressure,
heart rate, or blood lipid values. Even the STENO-2 study
failed to achieve those goals in most cases.
Changes in blood pressure and heart rate had no inﬂuence
on outcome in our study. We found a similar decrease in
blood pressure in both groups, despite the signiﬁcant
difference in our robust endpoints. Interestingly, the treat-
ment effect was also independent of heart rate reduction. In
our collective it appears that the statistically signiﬁcant
reduction of heart rate between baseline and follow-up in the
intensiﬁed group indicates excellent adherence to the treat-
ment, but seems to be only a surrogate of the depression of
the sympathetic system.
The only treatment target in our study was a decrease in
NT-proBNP concentrations. Contrary to our expectations,
the allocation to a treatment group did not result in a
signiﬁcant decrease of this biomarker. Based on our expe-
rience that changes in NT-proBNP are predictive over time,
we had hypothesized that the beneﬁcial effect of neurohu-
moral therapy would, conversely, result in a subsequent
decrease in concentration of the natriuretic peptides. In the
STENO-2 trial and also in a recent analysis where we had
tested the importance of changes in NT-proBNP on
outcome, NT-proBNP levels actually increased over time
(12,14). A separate study in a heart failure population
demonstrated that long-term beta-blocker therapy was
associated with decreased levels of plasma catecholamines
but no decrease in the concentration of natriuretic peptides
(24). Our data presented here do not allow us to draw
a sound conclusion on why a decrease in risk by an
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1371intervention did not result in a decrease of the biomarker.
We therefore conclude that NT-proBNP is an excellent
marker to select diabetic patients at risk of cardiac events,
but more research is needed to guide the treatment using
this biomarker, which has been proven to be effective in
selected cohorts in heart failure (25,26).
The treatment combination seems safe, based on the lack
of any adverse events requiring hospitalization during the
study. Interestingly, the glycemic control achieved was
signiﬁcantly better in the intensiﬁed group. Although there
was an aggressive up-titration of RAS antagonists and beta-
blockers in an already well-treated population, there were
no discontinuations of therapy or hospitalizations due to
hypotensive symptoms or for worsening renal function.
Among the reasons for this unexpected safety may be the
individualized, slow but steady titration phase, which took up
to 3 months. Another reason might have been the possibility
to contact the outpatient department for advice if side effects
emerged. It is worth noting that the glomerular ﬁltration rate
signiﬁcantly decreased in the intensiﬁed group, which is
a known and accepted effect of RAS inhibition (17,27).
Study limitations. A limitation of this trial was the absence
of patient randomization for treatment, as withholding RAS
antagonists is, at the very least, problematic based on the
guidelines. However, data from previous studies in which
patients were randomized for ACE inhibitor therapy argue
that patient randomization for treatment would have
increased the signiﬁcance of our results. Second, the great
majority of our patients were Caucasian; the results may not
be the same in people of other races or ethnicities.
Finally, our statistical analysis was based on group
comparisons without adjustment for additional covariates.
Due to the low event rates, the validity of the adjusted
models as shown in the appendix is limited and should be
interpreted with caution. Also, adjusting for NT-proBNP is
problematic as therapy and NT-proBNP are both functions
of risk. The treatment provided is probably not able to
surpass the risk mirrored by NT-proBNP. Therefore NT-
proBNP remains a signiﬁcant inﬂuencing factor superior
to the treatment effect. This at least was true for log-
transformed NT-proBNP (Online Table 3). The end-
points remained signiﬁcant, if NT-proBNP was included
as an absolute value in the adjusted model (Online Table 3).
Conclusions
Our data suggest that accelerated up-titration of RAS
antagonists and beta-blockers to maximum tolerated
dosages is an effective and safe intervention for the primary
prevention of cardiovascular events in a population of
patients with diabetes pre-selected using NT-proBNP.
Further study is required to validate these observations
in larger populations. Especially patients with low NT-
proBNP also have to be analyzed to test whether the
treatment effect is exclusively present in patients with
increased concentrations of NT-proBNP. We would expectthat based on the low event rates in a population with low
NT-proBNP the number to treat would be substantially
higher than in the population presented in the PONTIAC
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